Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.50 |
| ▸ | HTR3B | O95264 | 3/20 | 0.50 |
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.50 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11527143 | 0.93 | HTR3A (0.56) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL25106007 | 0.84 | CYP1A2 (0.57) | OGACYP1A2ALDH1A1HPGD | |
| SCHEMBL16134879 | 0.84 | CYP1A2 (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6350054 | 0.81 | HTR3E (0.49) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6352737 | 0.80 | CYP1A2 (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL18291520 | 0.80 | HRH4 (0.50) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL20249261 | 0.78 | HRH4 (0.47) | HRH4CYP1A2KDM4E | |
| SCHEMBL4527814 | 0.75 | HTR3A (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL6351786 | 0.75 | CHRNA7 (0.59) | HTR3AHRH4KDM4EALDH1A1TSHR | |
| SCHEMBL16430192 | 0.75 | OGA (0.45) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HTR3E 2380/4885HTR3B 2448/4885HTR3A 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.